| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2001;103:351.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
Chlamydia pneumoniae Infection in Circulating Human Monocytes Is Refractory to Antibiotic Treatment
From the Institute of Medical Microbiology and Hygiene (J.G., H.F., W.S., M.M.), the Department of Internal Medicine II (J.J., K.D., H.A.K.), and the Institute of Anatomy (M.K.), Medical University of Lübeck, Lübeck, Germany.
Correspondence to Matthias Maass, MD, Institute of Medical Microbiology and Hygiene, Medical University of Lübeck, Ratzeburger Allee 160, D-23538 Lübeck, Germany. E-mail maass{at}hygiene.mu-luebeck.de
Background—Recovery of the intracellular bacterium Chlamydia pneumoniae from atherosclerotic plaques has initiated large studies on antimicrobial therapy in coronary artery disease. The basic concept that antibiotic therapy may eliminate and prevent vascular infection was evaluated in vitro and in vivo by examining the antibiotic susceptibility of C pneumoniae in circulating human monocytes, which are thought to transport chlamydiae from the respiratory tract to the vascular wall.
Methods and Results—Blood monocytes (CD14+) from 2 healthy volunteers were obtained before and after oral treatment with azithromycin or rifampin and then inoculated with a vascular C pneumoniae strain and continuously cultured in the presence of the respective antibiotic. Progress of infection and chlamydial viability was assessed by immunogold-labeling and detection of C pneumoniae–specific mRNA transcripts. Circulating monocytes from patients undergoing treatment with experimental azithromycin for coronary artery disease were examined for C pneumoniae infection by cell culture. Antibiotics did not inhibit chlamydial growth within monocytes. Electron microscopy showed development of chlamydial inclusion bodies. Reverse transcription–polymerase chain reaction demonstrated continuous synthesis of chlamydial mRNA for 10 days without lysis of the monocytes. The in vivo presence of viable pathogen not eliminated by azithromycin was shown by cultural recovery of C pneumoniae from the circulating monocytes of 2 patients with coronary artery disease.
Conclusions—C pneumoniae uses monocytes as a transport system for systemic dissemination and enters a persistent state not covered by an otherwise effective antichlamydial treatment. Prevention of vascular infection by antichlamydial treatment may be problematic: circulating monocytes carrying a pathogen with reduced antimicrobial susceptibility might initiate reinfection or promote atherosclerosis by the release of proinflammatory mediators.
Key Words: Chlamydia pneumoniae • atherosclerosis • infection • azithromycin • rifampin
This article has been cited by other articles:
 |
|
 |
|
  H. Yamaguchi, S. Kamiya, T. Uruma, T. Osaki, H. Taguchi, T. Hanawa, M. Fukuda, H. Kawakami, H. Goto, H. Friedman, et al. Chlamydia pneumoniae Growth Inhibition in Cells by the Steroid Receptor Antagonist RU486 (Mifepristone) Antimicrob. Agents Chemother., June 1, 2008; 52(6): 1991 - 1998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bunk, I. Susnea, J. Rupp, J. T. Summersgill, M. Maass, W. Stegmann, A. Schrattenholz, A. Wendel, M. Przybylski, and C. Hermann Immunoproteomic Identification and Serological Responses to Novel Chlamydia pneumoniae Antigens That Are Associated with Persistent C. pneumoniae Infections J. Immunol., April 15, 2008; 180(8): 5490 - 5498. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rey-Ladino, X. Jiang, B. R. Gabel, C. Shen, and R. C. Brunham Survival of Chlamydia muridarum within Dendritic Cells Infect. Immun., August 1, 2007; 75(8): 3707 - 3714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Eickhoff, J. Thalmann, S. Hess, M. Martin, T. Laue, J. Kruppa, G. Brandes, and A. Klos Host Cell Responses to Chlamydia pneumoniae in Gamma Interferon-Induced Persistence Overlap Those of Productive Infection and Are Linked to Genes Involved in Apoptosis, Cell Cycle, and Metabolism Infect. Immun., June 1, 2007; 75(6): 2853 - 2863. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Spagnoli, S. Pucci, E. Bonanno, A. Cassone, F. Sesti, A. Ciervo, and A. Mauriello Persistent Chlamydia pneumoniae Infection of Cardiomyocytes Is Correlated with Fatal Myocardial Infarction Am. J. Pathol., January 1, 2007; 170(1): 33 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rupp, W. Solbach, and J. Gieffers Single-Nucleotide-Polymorphism-Specific PCR for Quantification and Discrimination of Chlamydia pneumoniae Genotypes by Use of a "Locked" Nucleic Acid. Appl. Envir. Microbiol., May 1, 2006; 72(5): 3785 - 3787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Uruma, H. Yamaguchi, M. Fukuda, H. Kawakami, H. Goto, T. Kishimoto, Y. Yamamoto, A. Tomoda, and S. Kamiya Chlamydia pneumoniae growth inhibition in human monocytic THP-1 cells and human epithelial HEp-2 cells by a novel phenoxazine derivative J. Med. Microbiol., December 1, 2005; 54(12): 1143 - 1149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Taylor-Robinson and J. Boman The failure of antibiotics to prevent heart attacks BMJ, August 13, 2005; 331(7513): 361 - 362. [Full Text] [PDF]
|
|
|
|
|
|
K. Wolf, E. Fischer, and T. Hackstadt Degradation of Chlamydia pneumoniae by Peripheral Blood Monocytic Cells Infect. Immun., August 1, 2005; 73(8): 4560 - 4570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Siewert, J. Rupp, M. Klinger, W. Solbach, and J. Gieffers Growth Cycle-Dependent Pharmacodynamics of Antichlamydial Drugs Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1852 - 1856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Pinchuk, B. C. Starcher, B. Livingston, A. Tvninnereim, S. Wu, E. Appella, J. Sidney, A. Sette, and B. Wizel A CD8+ T Cell Heptaepitope Minigene Vaccine Induces Protective Immunity against Chlamydia pneumoniae J. Immunol., May 1, 2005; 174(9): 5729 - 5739. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Anderson Infection, Antibiotics, and Atherothrombosis -- End of the Road or New Beginnings? N. Engl. J. Med., April 21, 2005; 352(16): 1706 - 1709. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rupp, T. Hellwig-Burgel, V. Wobbe, U. Seitzer, E. Brandt, and M. Maass Chlamydia pneumoniae infection promotes a proliferative phenotype in the vasculature through Egr-1 activation in vitro and in vivo PNAS, March 1, 2005; 102(9): 3447 - 3452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Opitz, S. Forster, A. C. Hocke, M. Maass, B. Schmeck, S. Hippenstiel, N. Suttorp, and M. Krull Nod1-Mediated Endothelial Cell Activation by Chlamydophila pneumoniae Circ. Res., February 18, 2005; 96(3): 319 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Mitusch, J. Luedemann, W. G. Wood, K. Berger, U. Schminke, M. Suter, C. Kessler, U. John, J. Rupp, M. Kentsch, et al. Asymptomatic Carotid Atherosclerosis Is Associated With Circulating Chlamydia pneumoniae DNA in Younger Normotensive Subjects in a General Population Survey Arterioscler. Thromb. Vasc. Biol., February 1, 2005; 25(2): 386 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. de Kruif, E. C.M. van Gorp, T. T. Keller, J. M. Ossewaarde, and H. ten Cate Chlamydia pneumoniae infections in mouse models: relevance for atherosclerosis research Cardiovasc Res, February 1, 2005; 65(2): 317 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Caronzolo, V. Lucini, M. Pannacci, S. Grosso, F. Colleoni, F. Fraschini, and F. Scaglione Glucocorticoids Increase In Vitro and In Vivo Activities of Antibiotics against Chlamydophila pneumoniae Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4878 - 4881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Tormakangas, H. Alakarppa, D. B. David, M. Leinonen, and P. Saikku Telithromycin Treatment of Chronic Chlamydia pneumoniae Infection in C57BL/6J mice Antimicrob. Agents Chemother., October 1, 2004; 48(10): 3655 - 3661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. F. Riska, A. Kutlin, P. Ajiboye, A. Cua, P. M. Roblin, and M. R. Hammerschlag Genetic and Culture-Based Approaches for Detecting Macrolide Resistance in Chlamydia pneumoniae Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3586 - 3590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Legan, O. Vraspir-Porenta, D. Kese, R. Zorc-Pleskovic, and M. Zorc Histopathologic Signs for the Inflammatory Role of Chlamydia pneumoniae in the High-Grade Atherosclerotic Coronary Artery Wall Angiology, September 1, 2004; 55(5): 525 - 531. [Abstract] [PDF]
|
|
|
|
 |
|
 P. B. Wyrick and S. T. Knight Pre-exposure of infected human endometrial epithelial cells to penicillin in vitro renders Chlamydia trachomatis refractory to azithromycin J. Antimicrob. Chemother., July 1, 2004; 54(1): 79 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gieffers, G. van Zandbergen, J. Rupp, F. Sayk, S. Kruger, S. Ehlers, W. Solbach, and M. Maass Phagocytes transmit Chlamydia pneumoniae from the lungs to the vasculature Eur. Respir. J., April 1, 2004; 23(4): 506 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Gieffers, J. Rupp, A. Gebert, W. Solbach, and M. Klinger First-Choice Antibiotics at Subinhibitory Concentrations Induce Persistence of Chlamydia pneumoniae Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1402 - 1405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Sander, K. Winbeck, J. Klingelhofer, T. Etgen, and B. Conrad Progression of Early Carotid Atherosclerosis Is Only Temporarily Reduced After Antibiotic Treatment of Chlamydia pneumoniae Seropositivity Circulation, March 2, 2004; 109(8): 1010 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. van Zandbergen, J. Gieffers, H. Kothe, J. Rupp, A. Bollinger, E. Aga, M. Klinger, H. Brade, K. Dalhoff, M. Maass, et al. Chlamydia pneumoniae Multiply in Neutrophil Granulocytes and Delay Their Spontaneous Apoptosis J. Immunol., February 1, 2004; 172(3): 1768 - 1776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Lindsberg and A. J. Grau Inflammation and Infections as Risk Factors for Ischemic Stroke Stroke, October 1, 2003; 34(10): 2518 - 2532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yamaguchi, H. Friedman, M. Yamamoto, K. Yasuda, and Y. Yamamoto Chlamydia pneumoniae Resists Antibiotics in Lymphocytes Antimicrob. Agents Chemother., June 1, 2003; 47(6): 1972 - 1975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rupp and M. Maass Egr-1, a Major Link Between Infection and Atherosclerosis? Circ. Res., May 16, 2003; 92 (9): e78 - e78. [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Kalayoglu, P. Libby, and G. I. Byrne Chlamydia pneumoniae as an Emerging Risk Factor in Cardiovascular Disease JAMA, December 4, 2002; 288(21): 2724 - 2731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sander, K. Winbeck, J. Klingelhofer, T. Etgen, and B. Conrad Reduced Progression of Early Carotid Atherosclerosis After Antibiotic Treatment and Chlamydia pneumoniae Seropositivity Circulation, November 5, 2002; 106(19): 2428 - 2433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Shor, P. Libby, P. M. Ridker, and A. Maseri Atherosclerosis: Lipid Infiltration or Chlamydia pneumoniae Infection? * Response Circulation, October 29, 2002; 106 (18): e135 - e136. [Full Text] [PDF]
|
|
|
|
|
|
A. F.M. Stone, M. A. Mendall, J.-C. Kaski, T. M. Edger, P. Risley, J. Poloniecki, A. J. Camm, and T. C. Northfield Effect of Treatment for Chlamydia pneumoniae and Helicobacter pylori on Markers of Inflammation and Cardiac Events in Patients With Acute Coronary Syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA) Circulation, September 3, 2002; 106(10): 1219 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Wizel, B. C. Starcher, B. Samten, Z. Chroneos, P. F. Barnes, J. Dzuris, Y. Higashimoto, E. Appella, and A. Sette Multiple Chlamydiapneumoniae Antigens Prime CD8+ Tc1 Responses That Inhibit Intracellular Growth of This Vacuolar Pathogen J. Immunol., September 1, 2002; 169(5): 2524 - 2535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Blasi, S Damato, R Cosentini, P Tarsia, R Raccanelli, S Centanni, and L Allegra Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment Thorax, August 1, 2002; 57(8): 672 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yamaguchi, S. Haranaga, R. Widen, H. Friedman, and Y. Yamamoto Chlamydia pneumoniae Infection Induces Differentiation of Monocytes into Macrophages Infect. Immun., May 1, 2002; 70(5): 2392 - 2398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Boman and M. R. Hammerschlag Chlamydia pneumoniae and Atherosclerosis: Critical Assessment of Diagnostic Methods and Relevance to Treatment Studies Clin. Microbiol. Rev., January 1, 2002; 15(1): 1 - 20. [Abstract] [Full Text]
|
|
|
|
|
|
P. Fan, F. Dong, Y. Huang, and G. Zhong Chlamydia pneumoniae Secretion of a Protease-Like Activity Factor for Degrading Host Cell Transcription Factors Is Required for Major Histocompatibility Complex Antigen Expression Infect. Immun., January 1, 2002; 70(1): 345 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Dreses-Werringloer, I. Padubrin, H. Zeidler, and L. Kohler Effects of Azithromycin and Rifampin on Chlamydia trachomatis Infection In Vitro Antimicrob. Agents Chemother., November 1, 2001; 45(11): 3001 - 3008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. U. Heuschmann, D. Neureiter, M. Gesslein, B. Craiovan, M. Maass, G. Faller, G. Beck, B. Neundoerfer, and P. L. Kolominsky-Rabas Association Between Infection With Helicobacter pylori and Chlamydia pneumoniae and Risk of Ischemic Stroke Subtypes: Results From a Population-Based Case-Control Study Stroke, October 1, 2001; 32(10): 2253 - 2258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Shor Mechanism of Arterial Infection by Chlamydia pneumoniae Circulation, September 25, 2001; 104 (13): e75 - e75. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Huhtinen, M. Puolakkainen, K. Laasila, M. Sarvas, A. Karma, and M. Leirisalo-Repo Chlamydial Antibodies in Patients with Previous Acute Anterior Uveitis Invest. Ophthalmol. Vis. Sci., July 1, 2001; 42(8): 1816 - 1819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Caligiuri, M. Rottenberg, A. Nicoletti, H. Wigzell, and G. K. Hansson Chlamydia pneumoniae Infection Does Not Induce or Modify Atherosclerosis in Mice Circulation, June 12, 2001; 103(23): 2834 - 2838. [Abstract] [Full Text] [PDF]
|
|